FENOFIBRATE MICRO CAPSULE

Država: Kanada

Jezik: angleščina

Source: Health Canada

Aktivna sestavina:

FENOFIBRATE

Dostopno od:

SANIS HEALTH INC

Koda artikla:

C10AB05

INN (mednarodno ime):

FENOFIBRATE

Odmerek:

200MG

Farmacevtska oblika:

CAPSULE

Sestava:

FENOFIBRATE 200MG

Pot uporabe:

ORAL

Enote v paketu:

30/100

Tip zastaranja:

Prescription

Terapevtsko območje:

FRIBIC ACID DERIVATIVES

Povzetek izdelek:

Active ingredient group (AIG) number: 0118895001; AHFS:

Status dovoljenje:

CANCELLED POST MARKET

Datum dovoljenje:

2017-07-31

Lastnosti izdelka

Page 1 of 38
PRODUCT MONOGRAPH
PR
FENOFIBRATE MICRO
FENOFIBRATE, MICRONIZED FORMULATION
Capsules (200 mg)
LIPID METABOLISM REGULATOR
Sanis Health Inc. Date of revision:
333 Champlain Street, Suite 102 February 13, 2014
Dieppe, New Brunswick
E1A 1P2
Submission Control number: 171447
Page 2 of 38
PRODUCT MONOGRAPH
PR
FENOFIBRATE MICRO
fenofibrate, micronized formulation
THERAPEUTIC CLASSIFICATION
Lipid Metabolism Regulator
ACTIONS AND CLINICAL PHARMACOLOGY
FENOFIBRATE MICRO
(fenofibrate, micronized formulation) lowers elevated serum lipids by
decreasing the low density lipoprotein (LDL) fraction rich in
cholesterol and the very low
density lipoprotein (VLDL) fraction rich in triglycerides. In
addition, fenofibrate increases the
high density lipoprotein (HDL) cholesterol fraction.
Fenofibrate appears to have a greater depressant effect on the VLDL
than on the low density
lipoproteins (LDL). Therapeutic doses of fenofibrate produce
elevations of HDL cholesterol, a
reduction in the content of the low density lipoproteins cholesterol,
and a substantial reduction in
the triglyceride content of VLDL.
The mechanism of action of fenofibrate has not been definitively
established. Work carried out
to date suggests that fenofibrate:
•
enhances the liver elimination of cholesterol as bile salts;
•
inhibits the biosynthesis of triglycerides and enhances the catabolism
of VLDL by
increasing the activity of lipoprotein lipase;
•
has an inhibitory effect on the biosynthesis of cholesterol by
modulating the activity
of HMG-CoA reductase.
Metabolism and Excretion
After oral administration with food, fenofibrate is rapidly hydrolysed
to fenofibric acid, the
active metabolite. In man it is mainly excreted through the kidney.
Half-life is about 20 hours.
In patients with severe renal failure, significant accumulation was
observed with a large increase
in half-life. Therefore, the dose of fenofibrate may need to be
reduced, depending on the rate of
creatinine clearance.
Distribution
Fenofibric acid is extensively bound (> 99 %) to